OncoMatch/Clinical Trials/NCT06730308
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Is NCT06730308 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Concurrent chemotherapy and Methylprednisolone for thymoma.
Treatment: Concurrent chemotherapy · Methylprednisolone — This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06730308 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify